News|Articles|December 26, 2025

Allergy in 2025: Year in Review

Fact checked by: Tim Smith

Significant advancements in allergy treatments emerge in 2025, including 4 FDA approved treatments for hereditary angioedema.

The past year saw significant progress in allergy and immunology, with multiple US Food & Drug Administration (FDA) approvals expanding treatment options for hereditary angioedema (HAE), including donidalorsen, sebetralstat, and garadacimab-gxii. Clinicians now have access to therapies that improve attack prevention, offer oral and less frequent dosing options, and provide new tools for pediatric patients, addressing long-standing gaps in care.

Related to this article

October 8th, 2026

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

Colleen M. Shannon, MD, MPH Credit: Children's Hospital of Philadelphia

October 13th, 2026

Infant Anaphylaxis Often Resolves After a Single Epinephrine Dose

Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.

October 9th, 2026

Oral Deucrictibant Speeds Relief of Hereditary Angioedema Attacks

In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.

October 7th, 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

October 13th, 2026

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

October 13th, 2026

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.

October 13th, 2026

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

October 13th, 2026

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.

​​Allergy in 2025: Year in Review

Related to this article

Allergy in 2025: Year in Review